All-atoms MD simulations study of newly designed ciprofloxacin derivatives as potential bacterial DHPS and DNA gyrase inhibitors
TL;DR
A series of ciprofloxacin-sulfonamide hybrid molecules was designed, in which each pharmacophore retains its established mechanism of action and CIS4, CIS5, and CIS12 emerged as the most promising dual-target inhibitor of bacterial DHPS and DNA gyrase.
Abstract
The widespread use of antibiotics, particularly ciprofloxacin, has accelerated the emergence of antibiotic-resistant bacteria, posing a major public health challenge. Limited investment and declining pharmaceutical interest have slowed the discovery of new antibiotics, contributing to the increasing prevalence of multidrug-resistant (MDR) infections, especially those caused by ESKAPE pathogens. Uropathogenic Escherichia coli (UPEC), a leading cause of urinary tract infections (UTIs), develops multidrug resistance through mechanisms including drug target modification and reduced antibiotic susceptibility. In the present study, a series of ciprofloxacin-sulfonamide hybrid molecules (CIS1-CIS15) was designed, in which each pharmacophore retains its established mechanism of action. Ciprofloxacin inhibits DNA gyrase and topoisomerase IV, whereas sulfonamides inhibit dihydropteroate synthase (DHPS) by competing with para-aminobenzoic acid (PABA) in the bacterial folate biosynthetic pathway. Accordingly, the designed hybrids were computationally evaluated against both enzymatic targets to investigate their potential dual-target antibacterial activity. Molecular docking and molecular dynamics (MD) simulations were performed to assess the binding affinity and stability of the ciprofloxacin-bearing sulfonamide derivatives (CIS1-CIS15) against DNA gyrase and Staphylococcus aureus DHPS. Principal component analysis (PCA) and free-energy landscape (FEL) analysis were used to characterize the conformational flexibility and low-energy states of the protein–ligand complexes, while MD simulations validated the stability of the highest-scoring docked complexes. Among the designed derivatives, CIS4 (ciprofloxacin-sulfamethoxazole), CIS5 (ciprofloxacin–sulfaguanidine), and CIS12 (ciprofloxacin-sulfamerazine) exhibited the strongest binding affinity toward both targets while maintaining conformational stability throughout the simulations. Structural analysis of the pre- and post-MD trajectories identified Arg52, Lys39, Arg88, Lys94, Lys120, Glu201, and Lys203 as key residues involved in ligand recognition. Overall, CIS4, CIS5, and CIS12 emerged as the most promising dual-target inhibitor of bacterial DHPS and DNA gyrase. These findings provide valuable structural insights for the rational design of novel fluoroquinolone-based antibacterial agents and demonstrate the utility of computational approaches in identifying potential therapeutics against drug-resistant bacterial pathogens.